Clinical Trial

A Clinical Study of BioTTT001 in Combination With Toripalimab and Regorafenib in Patients With Colorectal Cancer

Not Yet Recruiting Phase 1
View on ClinicalTrials.gov →
Summary
This is a phase I, open-label clinical study of BioTTT001 in combination with Toraplizumab and Regorafenib in patients with liver metastases from colorectal cancer.
Protocol Amendment History 2 amendments
This ClinicalTrials.gov record has been amended 2 times since 2024-02-22; most recent amendment 2026-01-04.
Trial Details
NCT Number NCT06283134
Lead Sponsor China Medical University, China
Collaborators: Beijing Bio-Targeting Therapeutics Technology Co., Ltd
Conditions Colorectal Cancer Metastatic
Enrollment 60 participants
Start Date 2026-03
Primary Completion 2027-12-01 (estimated)
Study Completion 2028-12-01 (estimated)
Updated on ClinicalTrials.gov 2026-01-07